[1]程纷纷,闫波.心肌纤维化与舒张性心力衰竭相关性研究进展[J].慢性病学杂志,2018,(12):1676-1680.
点击复制
心肌纤维化与舒张性心力衰竭相关性研究进展(PDF)
《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]
- 卷:
- 期数:
- 2018年12期
- 页码:
- 1676-1680
- 栏目:
- 综 述
- 出版日期:
- 2018-12-30
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- R541.6
- DOI:
- -
- 摘要:
- 舒张性心力衰竭又称左心室射血分数（LVEF） 保留的心力衰竭（HFpEF），相对LVEF 降低的心力衰竭 （HFrEF） 而言，其特点是具有心力衰竭的临床表现，但LVEF 正常或接近正常（>50%），且有舒张功能不全的 证据。目前，HFpEF 患病率逐步上升，严重影响患者的生活质量及寿命，且预后较HFrEF 更差。但目前HFpEF 的发病机制仍不明确，尚无标准的诊断和治疗方法，增加了HFpEF 患者的管理难度。最近的研究表明，心 肌纤维化与HFpEF 存在明显的相关性，充分了解心肌纤维化与HFpEF 的关系有助于临床更好地诊断和治疗 HFpEF。
- Abstract:
- -
参考文献/References:
[1] Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart
failure with preserved ejection fraction [J]. Nat Rev Cardiol,
2014,10(3):377-388.
[2] Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in
patients hospitalized with heart failure and preserved left
ventricular ejection fraction: prevalence, therapies, and outcomes
[J]. Circulation, 2012,126(1):65-75.
[3] Gavryushina SV. Heart failure with preserved left ventricular
ejection fraction: epidemiology, patient, clinic and diagnostics
[J]. Kardiologiia, 2018,(S4):55-64.
[4] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/
AHA guideline for the management of heart failure: a report
of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines
[J]. J Am Coll Cardiol, 2013,62(16):e147-239.
[5] Sciarretta S, Paneni F, Palano F, et al. Role of the reninangiotensin-
aldosterone system and inflammatory processes
in the development and progression of diastolic dysfunction
[J]. Clin Sci (Lond), 2009,116(6):467-77.
[6] Zakeri R, Moulay G, Chai Q, et al. Left Atrial Remodeling
and Atrioventricular Coupling in a Canine Model of
Early Heart Failure With Preserved Ejection Fraction [J].
Circ Heart Fail,2016,9(10):e003238..
[7] Ter Maaten JM, Damman K, Verhaar MC, et al. Connecting
heart failure with preserved ejection fraction and renal
dysfunction: the role of endothelial dysfunction and inflammation
[J]. Eur J Heart Fail, 2016,18(6):588-598.
[8] Aikawa T, Naya M, Obara M, et al. Impaired Myocardial
Sympathetic Innervation Is Associated with Diastolic Dys-function in Heart Failure with Preserved Ejection Fraction:
C-Hydroxyephedrine PET Study [J]. J Nucl Med, 2017,58
(5):784-790.
[9] Ellims AH, Shaw JA, Stub D, et al. Diffuse myocardial
fibrosis evaluated by post- contrast t1 mapping correlates
with left ventricular stiffness [J]. J Am Coll Cardiol, 2014,
63(11):1112-1118.
[10] Hamdani N. Myocardial titin and collagen in cardiac diastolic
dysfunction: partners in crime [J]. Circulation, 2013,
128(1):5-8.
[11] Zile MR, Baicu CF, Ikonomidis JS, et al. Myocardial stiffness
in patients with heart failure and a preserved ejection
fraction: contributions of collagen and titin [J]. Circulation,
2015,131(14):1247-1259.
[12] Rech M, Barandiarán Aizpurua A, van Empel V, et al.
Pathophysiological understanding of HFpEF: microRNAs
as part of the puzzle [J]. Cardiovasc Res, 2018,114(6):782-
793.
[13] Dong S, Ma W, Hao B, et al. microRNA- 21 promotes
cardiac fibrosis and development of heart failure with preserved
left ventricular ejection fraction by up- regulating
Bcl-2 [J]. Int J Clin Exp Pathol, 2014,157(2):565-574.
[14] Tamaki S, Mano T, Sakata Y, et al. Interleukin- 16 promotes
cardiac fibrosis and myocardial stiffening in heart
failure with preserved ejection fraction [J]. PLoS One,
2013,8(7):e68893.
[15] Mewton N, Liu CY, Croisille P, et al. Assessment of
myocardial fibrosis with cardiovascular magnetic resonance
[J]. J Am Coll Cardiol, 2011,57(8):891-903.
[16] Su MY, Lin LY, Tseng YH, et al. CMR- verified diffuse
myocardial fibrosis is associated with diastolic dysfunction
in HFpEF [J]. JACC Cardiovasc Imaging, 2014,7(10):991-
997.
[17] Sciarretta S, Paneni F, Palano F, et al. Role of the reninangiotensin-
aldosterone system and inflammatory processes
in the development and progression of diastolic dysfunction
[J]. Clin Sci (Lond) , 2009,116(6):467-477.
[18] Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and
significance of alterations in cardiac structure and function
in patients with heart failure and a preserved ejection fraction
[J]. Circulation, 2011,124(23):2491-2501.
[19] Xu B. Utility of Echocardiography in Heart Failure with
Preserved Ejection Fraction [J]. J Card Fail, 2018,24(6):
397-403.
[20] Petrie MC, Hogg K, Caruana L. Poor concordance of
commonly used echocardiographic measures of left ventricular
diastolic function in patients with suspected heart failure
but preserved systolic function: is there a reliable echocardiographic
measure of diastolic dysfunction [J]. Heart,
2004,90(5):511-517.
[21] Mottram PM, Leano R. Usefulness of B- type natriuretic
peptide in hypertensive patients with exertional dyspnea
and normal left ventricular ejection fraction and correlation
with new echocardiographic indexes of systolic and diastolic
function [J]. Am J Cardiol, 2003,92(12):1434-1438.
[22] Oren O. Heart Failure with Preserved Ejection Fraction:
Diagnosis and Management [J]. Am J Med, 2017,130(5):
510-516.
[23] Webb J, Fovargue L, T?ndel K, et al. The Emerging
Role of Cardiac Magnetic Resonance Imaging in the Evaluation
of Patients with HFpEF [J]. Curr Heart Fail Rep,
2018,15(1):1-9.
[24] Zile MR. Biomarkers of diastolic dysfunction and myocardial
fibrosis: application to heart failure with a preserved
ejection fraction [J]. J Cardiovasc Transl Res, 2013,6(4):
501-515.
[25] Duprez DA, Gross MD, Kizer JR, et al. Predictive Value
of Collagen Biomarkers for Heart Failure With and Without
Preserved Ejection Fraction: MESA (Multi- Ethnic
Study of Atherosclerosis) [J]. J Am Heart Assoc, 2018,7
(5):e007885.
[26] Barasch E, Gottdiener JS, Aurigemma G, et al. Association
between elevated fibrosis markers and heart failure in
the elderly: the cardiovascular health study [J]. Circ Heart
Fail, 2009,2(4):303-310.
[27] Agarwal I, Glazer NL, Barasch E, et al. Fibrosis- related
biomarkers and incident cardiovascular disease in older
adults: the cardiovascular health study [J]. Circ Arrhythm
Electrophysiol, 2014,7(4):583-589.
[28] Martos R, Baugh J, Ledwidge M, et al. Diagnosis of
heart failure with preserved ejection fraction: improved accuracy
with the use of markers of collagen turnover [J].
Eur J Heart Fail, 2009,11(2):191-197.
[29] Ansari U, Behnes M, Hoffmann J, et al. Galectin- 3 Reflects
the Echocardiographic Grades of Left Ventricular Diastolic
Dysfunction [J]. Ann Lab Med, 2018,38(4):306-
315.
[30] Zhang ZY, Ravassa S, Yang WY, et al. Diastolic Left
Ventricular Function in Relation to Urinary and Serum
Collagen Biomarkers in a General Population [J]. PLoS
One, 2016,11(12):e0167582.
[31] Zhang Q, Chen Y, Liu Q. Effects of renin- angiotensinaldosterone
system inhibitors on mortality, hospitalization,
and diastolic function in patients with HFpEF A metaanalysis
of 13 randomized controlled trials [J]. Herz, 2016,
41(1):76-86.
[32] 何倩雯,冯英,文印宪,等.ACEI/ARBCEI/ARB 治疗舒张性心
力衰竭疗效及安全性的系统评价[J].中国循证医学杂志,2015,15
(6):672-680.
[33] Pandey A, Garg S, Matulevicius SA, et al. Effect of Mineralocorticoid
Receptor Antagonists on Cardiac Structure
and Function in Patients With Diastolic Dysfunction andHeart Failure With Preserved Ejection Fraction: A Meta-
Analysis and Systematic Review [J]. J Am Heart Assoc,
2015,4(10):e002137.
[34] Li MJ, Huang CX, Okello E, et al. Treatment with spironolactone
for 24 weeks decreases the level of matrix metalloproteinases
and improves cardiac function in patients
with chronic heart failure of ischemic etiology [J]. Can J
Cardiol, 2009,25(9):523-526.
[35] Ravassa S, Trippel T, Bach D, et al. Biomarker- based
phenotyping of myocardial fibrosis identifies patients with
heart failure with preserved ejection fraction resistant to
the beneficial effects of spironolactone: results from the Aldo-
DHF trial [J]. Eur J Heart Fail, 2018.
[36] Kurrelmeyer KM, Ashton Y, Xu J, et al. Effects of spironolactone
treatment in elderly women with heart failure
and preserved left ventricular ejection fraction [J]. J Card
Fail,2014,20(8):560-568.
[37] Kosmala W, Rojek A, Przewlocka-Kosmala M, et al. Effect
of Aldosterone Antagonism on Exercise Tolerance in
Heart Failure With Preserved Ejection Fraction [J]. J Am
Coll Cardiol , 2016,68(17):1823-1834.
[38] Bonsu KO, Arunmanakul P. Pharmacological treatments
for heart failure with preserved ejection fraction- a systematic
review and indirect comparison [J]. Heart Fail Rev,
2018,23(2):147-156.
[39] Azevedo CF, Nigri M, Higuchi ML, et al. Prognostic significance
of myocardial fibrosis quantification by histopathology
and magnetic resonance imaging in patients with severe
aortic valve disease [J]. J Am Coll Cardiol, 2010,56
(4):278-287.
[40] Barasch E, Gottdiener JS, Aurigemma G, et al. The relationship
between serum markers of collagen turnover and
cardiovascular outcome in the elderly: the Cardiovascular
Health Study [J]. Circ Heart Fail, 2011,4(6):733-739.
[41] Kitahara T, Takeishi Y, Arimoto T, et al. Serum carboxy-
terminal telopeptide of type I collagen (ICTP) predicts
cardiac events in chronic heart failure patients with
preserved left ventricular systolic function [J]. Circ J, 2007,
71(6):929-935.
备注/Memo
- 备注/Memo:
-
作者简介：程纷纷，硕士研究生，研究方向：心血管疾病
通信作者：闫波，E-mail: yanbo@mail.jmnc.edu.cn
常用功能
统计/Statistics
- 摘要浏览/Viewed845
- 全文下载/Downloads753
- 评论/Comments
